Spartalizumab (anti-PD-1)

目录号：A2017 批次号: A201703

Spartalizumab (anti-PD-1)是一种针对PD-1的人源IgG4抗体，抑制PD-L1和PD-L2与PD-1的结合。PDR001可与PD-1以高亲和力结合，抑制其生物活性；MW: 145.8 KD。

CAS号	1935694-88-4
配制	PBS buffer, pH 7.2
推荐同型对照	Human IgG4
来源	CHO cells
储存条件 (自收到货起)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
纯度	99%
蛋白浓度	4.54 mg/ml
内毒素	<1 EU/mg

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. [ Elife, 2020, 9]	PubMed: 32091388

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. [ Elife, 2020, 9]

PubMed: 32091388

禁止用于人体及治疗！